Patents by Inventor Robert C. Ladner

Robert C. Ladner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9873957
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: January 23, 2018
    Assignee: Dyax Corp.
    Inventor: Robert C. Ladner
  • Patent number: 9480733
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 1, 2016
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • Patent number: 9388510
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: July 12, 2016
    Assignee: Dyax Corp.
    Inventor: Robert C. Ladner
  • Patent number: 9382535
    Abstract: Methods useful in constructing libraries that collectively display members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: July 5, 2016
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet
  • Patent number: 9114144
    Abstract: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 25, 2015
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams, Maria Grazia De Simoni, Luigi Bergamaschini
  • Patent number: 9051377
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 9, 2015
    Assignee: Dyax Corp.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx
  • Patent number: 8901045
    Abstract: Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: December 2, 2014
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Publication number: 20140349940
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 27, 2014
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • Patent number: 8846579
    Abstract: Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: September 30, 2014
    Inventors: Hendricus Renerus Jacobus Mattheus Hoogenboom, Jurgen Mullberg, Robert C. Ladner
  • Patent number: 8828703
    Abstract: Proteins including engineered sequences which inhibit proteases are disclosed, including proteins having two or more engineered Kunitz domains, and uses of such proteins.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: September 9, 2014
    Assignee: Dyax Corp.
    Inventor: Robert C. Ladner
  • Patent number: 8716225
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 6, 2014
    Assignee: DYAX Corp.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Patent number: 8710007
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 29, 2014
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • Patent number: 8663629
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: March 4, 2014
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Patent number: 8642010
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: February 4, 2014
    Assignees: Dyax Corp., Bracco Suisse SA
    Inventors: Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert C. Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Feng Yan, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski
  • Publication number: 20130274112
    Abstract: Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells.
    Type: Application
    Filed: April 22, 2013
    Publication date: October 17, 2013
    Inventors: Henricus R J. Hoogenboom, Jurgen Mullberg, Robert C. Ladner
  • Patent number: 8557743
    Abstract: Disclosed are methods of selecting phage encoding a target binding protein. The methods can include forming a mixture comprising a plurality of diverse display phage, a target, and a support, and forming phage immobilized to the support, each of which comprises a phage which binds the target and the target immobilized to the support. Phage that do not bind to the target are separated. Host cells are contacted with the phage immobilized to the support via binding to the target so that the host cells are infected by the phage immobilized to the support. Replicate phage are produced from the infected cells in the presence of the target immobilized to the support, thereby forming replicate phage immobilized to the support via binding to the support. Replicate phage that do not bind to the target are separated. Host cells are contacted with the replicate phage immobilized to the support.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: October 15, 2013
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Shannon Hogan, Kristin Rookey
  • Patent number: 8551920
    Abstract: The disclosure features methods for identifying antibodies that bind to a carbohydrate moiety. Libraries coding for antibodies that bind to a carbohydrate moiety are provided. The libraries can be provided by modifying a pre-existing nucleic acid library. Antibodies that bind to a carbohydrate moiety are described.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: October 8, 2013
    Assignee: Morpho Sys AG
    Inventors: Rene Hoet, Sonia Schoonbroodt, Robert C. Ladner
  • Patent number: 8445410
    Abstract: Disclosed is a method that includes: (i) providing a plurality of initial nucleic acid cassettes that include: a) a first coding region encoding a first immunoglobulin variable domain, b) a second coding region encoding a second immunoglobulin variable domain, and c) a ribosomal binding site disposed between the first and second coding regions for translation of the second polypeptide in a first expression system, wherein the first and second coding regions are in the same translational orientation; (ii) modifying each nucleic acid cassette of the plurality in a single reaction mixture so that it is functional in a second expression system, wherein the first and second region remain physically attached during the modifying; (iii) introducing each modified nucleic acid cassette into a mammalian cell to produce a mixture of transfected cells; and (iv) expressing each modified nucleic acid cassette in the transfected cells.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: May 21, 2013
    Assignee: DYAX Corp.
    Inventors: Henricus Renerus Jacobus Mattheus Hoogenboom, Jurgen Mullberg, Robert C. Ladner
  • Patent number: 8431359
    Abstract: This invention features novel proteins that are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and are capable of inhibiting plasmin and nucleic acids encoding these proteins. The invention also features the use of such proteins in therapeutic, diagnostic, and clinical methods.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 30, 2013
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • Publication number: 20130040861
    Abstract: Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed.
    Type: Application
    Filed: May 4, 2012
    Publication date: February 14, 2013
    Applicant: DYAX CORP.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom